Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Retained Earnings: 2022-2024

Historic Retained Earnings for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to -$988.7 million.

  • Centessa Pharmaceuticals' Retained Earnings fell 27.66% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 27.66%. This contributed to the annual value of -$988.7 million for FY2024, which is 31.31% down from last year.
  • As of FY2024, Centessa Pharmaceuticals' Retained Earnings stood at -$988.7 million, which was down 31.31% from -$752.9 million recorded in FY2023.
  • Centessa Pharmaceuticals' Retained Earnings' 5-year high stood at -$601.9 million during FY2022, with a 5-year trough of -$988.7 million in FY2024.
  • For the 3-year period, Centessa Pharmaceuticals' Retained Earnings averaged around -$781.2 million, with its median value being -$752.9 million (2023).
  • Data for Centessa Pharmaceuticals' Retained Earnings shows a maximum YoY plummeted of 31.31% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Centessa Pharmaceuticals' Retained Earnings stood at -$601.9 million in 2022, then fell by 25.10% to -$752.9 million in 2023, then tumbled by 31.31% to -$988.7 million in 2024.